Highlights Daiichi Sankyo Company, Limited

Stocks

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:30:00 09/06/2026 BST			5-day change	1st Jan Change
2,559.00 ^JPY	+1.21%		-2.29%	-23.57%

06-05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
05-28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE

Highlights

05-28	Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO	CI
05-22	Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S	CI
05-22	Daiichi Sankyo and Astrazeneca Announce Enhertu's Recommendation for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	CI
05-21	Astrazeneca Receives CHMP Recommendation for Enhertu Approval in the Eu for Previously Treated Her2-Positive Metastatic Solid Tumours	CI
05-21	Daiichi Sankyo and Astrazeneca Receive U.S. Approval for Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in Patients Not Eligible for Pd-1/Pd-L1 Inhibitors	CI
05-16	Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer	CI
05-15	FDA approves Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki for two breast cancer indications	RE
05-11	Daiichi Sankyo's Attributable Profit Falls 12% in Fiscal Year 2025	MT
05-11	Daiichi Sankyo Co Ltd - to cancel 31,457,200 shares, 1.73% of issued shares	RE
05-11	Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
05-11	Daiichi Sankyo Company, Limited Proposes Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 23, 2026; Provides Dividend Guidance for the Second Quarter End and Fiscal Year Ending March 31, 2027	CI
05-11	Daiichi Sankyo Company, Limited Reports Earnings Results for the Full Year Ended March 31, 2026	CI
05-08	Daiichi Sankyo Co Ltd - Occurrence of losses related to review of product supply plans	RE
05-07	Daiichi Sankyo Company, Limited Revises Consolidated Earnings Guidance for the Fiscal Year Ended March 31, 2026	CI
05-07	Daiichi Sankyo Company, Limited Provides Non-Consolidated Earnings Guidance for the Year Ended March 31, 2026	CI
04-27	Daiichi Sankyo Delays Release of Fiscal Year 2025 Results to May 11 for Further Review	MT
04-24	Daiichi Sankyo Raises Full-Year Forecasts on Forex Gains	MT
04-24	Daiichi Sankyo Delays Earnings Release Amid Oncology Portfolio Review; Shares Fall 10%	MT
04-24	Daiichi Sankyo Co Ltd - Daiichi Sankyo announces rescheduling of announcement of consolidated financial results for year ended March 31, 2026	RE
04-16	Interna Therapeutics and Daiichi Sankyo Enters Research Collaboration to Advance Mnm-Based Targeted Delivery Technologies	CI
04-15	Wayfinder Biosciences and Daiichi Sankyo Advance Research Collaboration on Key Neurodegeneration Target to Second Phase	CI
04-15	Daiichi Sankyo to Sell Over-the-Counter Drug Business for $1.55 Billion	DJ
04-15	Suntory Eyes Daiichi Sankyo Healthcare in 200 Billion Yen Deal	MT
04-15	Suntory Holdings Ltd - By welcoming Daiichi Sankyo healthcare to Suntory group, expect to expand business across self-care and self-medication domains	RE
04-15	Daiichi Sankyo Co Ltd - to transfer Daiichi Sankyo healthcare stock to Suntory Holdings	RE